WeConnectPatients.com · Cancer Care

Colorectal cancer is not one disease. It’s yours. And your options are growing.

Whether you’re newly diagnosed, mid-treatment, or watching someone you love go through it — this page breaks down what colorectal cancer actually is, how it’s treated, and why the science happening right now matters.

New Cases/Year

Diagnosed annually in the United States

Most Common

Cancer in both men and women

Survival (Early)

Five-year survival when caught at a localized stage

Annual Rate Increase

Annual rise in incidence rate of colorectal cancer in adults under 50

Your colon or rectum — that’s where it starts. What happens next depends on when it’s found.

Colorectal cancer begins when cells in the lining of the colon or rectum grow out of control. Sometimes it starts as a small polyp that sits quietly for years. Sometimes it shows up with bleeding or pain that gets brushed off as something else.

It’s the third most common cancer in the U.S. — about 150,000 people hear this diagnosis every year. And while overall rates have been declining in older adults thanks to screening, something troubling is happening in younger people: cases in adults under 50 are rising 1–2% per year in incidence rate.

That shift matters. It means colorectal cancer (CRC) isn’t just an older person’s disease anymore. If you’re under 50 and you have persistent changes in your bowel habits, rectal bleeding, or unexplained fatigue — take those symptoms seriously. Don’t accept “you’re too young to have colorectal cancer” as a final answer.

The biology of CRC matters too. About 15% of colorectal cancers have a specific molecular feature called MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficiency). These terms describe a pattern in the tumor’s DNA repair system. That distinction changes how the disease is treated — it can mean immunotherapy instead of chemotherapy as a first option. Your tumor’s molecular profile isn’t just lab data. It’s a roadmap.

When caught early, survival rates are excellent — above 90% for localized disease. When it’s metastatic (meaning it has spread to other parts of the body), that number drops significantly. This is why screening and early detection aren’t just medical recommendations. They’re the single most powerful tool you have.

What raises the risk

No single cause. But some things clearly raise the risk — and a few of them are within your control.

Age and trends

Most cases occur after age 50. But early-onset colorectal cancer is rising in younger adults. The screening age was lowered to 45 in 2021 for a reason.

Family history and genetics

If a parent, sibling, or child had colorectal cancer, your risk is higher. Hereditary conditions like Lynch syndrome and familial adenomatous polyposis raise it significantly.

Inflammatory bowel disease

Long-standing ulcerative colitis or Crohn’s disease increases colorectal cancer risk two to three times. Regular surveillance colonoscopy is essential.

Lifestyle factors

Obesity, heavy alcohol use, smoking, processed meat, and a sedentary lifestyle all raise risk. These aren’t guilt trips — they’re areas where small shifts can matter.

Racial disparities

African Americans have both higher incidence and higher mortality from colorectal cancer. The reasons are structural: screening access gaps, treatment delays, provider bias. This isn’t biology. It’s inequity.

Screening is prevention

Colonoscopy doesn’t just detect cancer. It prevents it — by finding and removing polyps before they become dangerous. Published studies suggest that screening can reduce colorectal cancer incidence by up to 70–90% in consistently screened populations, with colonoscopy showing the greatest protective effect.

How colorectal cancer is found

How it’s found depends partly on whether you had symptoms or a screening caught it first.

Screening colonoscopy

The gold standard. A camera examines the entire colon and rectum. Polyps are removed on the spot. Current guidelines say start at age 45 for average-risk adults — earlier if you have family history. If cost or access to colonoscopy is a concern, stool-based tests like FIT or Cologuard are covered alternatives — ask your healthcare provider or contact your local health department about no-cost screening programs in your area.

Alternative screening options

Not ready for a colonoscopy? Stool-based tests like FIT and Cologuard can detect signs of cancer or precancerous changes from home. They’re not a replacement for colonoscopy, but they’re better than skipping screening entirely.

Diagnostic workup

If something is found, you’ll get imaging (CT scans), blood work (including CEA, a tumor marker protein in the blood), and a biopsy to confirm cancer and determine the stage.

Molecular profiling

Your tumor will be tested for specific molecular markers — including MSI-H/dMMR (which affects immunotherapy eligibility) and KRAS/BRAF mutations (which affect targeted therapy options). These results directly determine which treatments will work best for you. Ask your oncologist to walk you through your results.

Staging

Stage 1 is localized. Stage 4 means it has spread. Your stage, combined with your molecular profile and overall health, guides every treatment decision from here.

Treatment depends on your biology

Your stage, your tumor’s molecular profile, and your overall health all shape the plan. There’s no single path — but there are real options at every stage.

Foundation

Surgery

The primary treatment for most non-metastatic colorectal cancer. Surgeons remove the tumor and nearby lymph nodes. Minimally invasive techniques are standard when possible, with faster recovery times.

Systemic Treatment

Chemotherapy

Standard chemotherapy combinations — known as FOLFOX and FOLFIRI — are the backbone of treatment for stage 3 and metastatic disease. These regimens combine multiple medications to target cancer cells. They work. They also carry real side effects — nausea, fatigue, neuropathy. Modern supportive care has made these more manageable.

Precision Medicine

Immunotherapy

If your tumor is MSI-H or dMMR (about 15% of cases), immunotherapy can be used as a first-line treatment instead of chemotherapy. For the right patients, it means improved outcomes with fewer side effects.

Biomarker-Driven

Targeted Therapy

Certain medications — called anti-VEGF and anti-EGFR agents — block specific signals that help cancer cells grow. Your extended RAS mutation status (which includes KRAS and NRAS) and BRAF mutation status together determine whether these drugs are likely to work for you. This is why comprehensive molecular profiling at diagnosis matters.

Planning Ahead

Fertility & Reproductive Health

If you are of reproductive age, talk to your oncologist about fertility preservation options before starting treatment. Surgery, chemotherapy, and radiation can all affect fertility — but options exist, and timing matters. A referral to a reproductive specialist can happen alongside your cancer treatment planning.

All treatments carry potential side effects. Talk to your oncologist about which risks and benefits apply to your specific situation.

“I thought stage 4 meant no options. Turns out, it meant different options. My doctor matched my treatment to my tumor’s biology — not just to a protocol.”

Reflects common patient experiences

If cost or access is a concern, ask about patient assistance programs. In some clinical trials, the investigational treatment is provided as part of the study — talk to your healthcare team about what participation involves before making any decisions.

Answers to common questions

Living with or after colorectal cancer raises real, practical questions. Here are honest answers to some of the most common ones.

Is colorectal cancer preventable?

In many cases, yes. Screening colonoscopy can find and remove polyps before they become cancer. That’s not just early detection — it’s actual prevention. The biggest barrier isn’t the disease. It’s not getting screened.

I’m under 50. Should I be worried?

If you have symptoms — changes in bowel habits, rectal bleeding, unexplained weight loss, persistent fatigue — yes, take them seriously regardless of your age. Early-onset CRC is rising. Don’t accept “you’re too young” as an answer.

What does MSI-H mean for me?

It means your tumor has a specific molecular feature that makes it respond well to immunotherapy. About 15% of colorectal cancers are MSI-H. If yours is, your treatment plan may look very different — and often more favorable — than standard chemotherapy. Make sure your tumor has been tested.

Will I need a colostomy bag?

Maybe temporarily, maybe not at all. It depends on where your tumor is and what surgery you need. Many colostomies are reversed after healing. If it does become permanent, it’s more manageable than most people expect. Ask your healthcare team for a referral to an ostomy nurse — and organizations like the United Ostomy Associations of America (uoaa.org) offer both in-person and online support groups.

How do I handle the emotional side?

Cancer changes everything for a while. Fear, grief, anger — all of it is normal. Depression and anxiety are more common than people admit. Ask for a referral to a psychologist or social worker who works with cancer patients. This isn’t weakness. It’s smart.

Are there racial disparities in colorectal cancer?

Yes. African Americans face higher incidence and higher mortality. This is driven by unequal screening access, treatment delays, and systemic bias — not biology. If you feel you’re not getting the same quality of care, advocate for yourself or bring someone who will.

What support organizations should I know about?

The Colorectal Cancer Alliance and Fight Colorectal Cancer are the two biggest. The American Cancer Society has broad resources too. Online communities can connect you with people who understand what you’re going through.

How do I talk to my family about genetic risk?

If you’ve been diagnosed — especially under 50 — your close relatives should know. Lynch syndrome and other hereditary conditions mean your family members may need earlier screening. A genetic counselor can help guide the conversation and the testing.

Research & Progress

The science is moving fast

The landscape of colorectal cancer treatment is changing faster than most people realize. For the roughly 15% of patients whose tumors are MSI-H or dMMR, first-line immunotherapy is already an approved treatment option that has significantly improved outcomes. Researchers are now working on ways to extend immunotherapy benefits to the remaining 85% of colorectal cancers — the MSS (microsatellite-stable) tumors that don’t currently respond to it. New combinations of chemotherapy, targeted agents, and immune-based approaches are in clinical trials right now.

Liquid biopsies — blood tests that detect fragments of tumor DNA circulating in the bloodstream — are an active area of research for monitoring treatment response and detecting recurrence. Some applications are already used in clinical practice; others are still being validated in clinical trials. And for younger patients with early-onset disease, research is beginning to uncover the biological drivers that make their cancers behave differently.

As of early 2026, clinical trials are where many of these advances become available before they reach standard of care. Participating means access to specialized teams, newer therapies, and close monitoring. It also means contributing to the science that will shape treatment for the next generation. No pressure. Just options.

You have more options than you think. And some of them are available right now.

Colorectal cancer research is advancing rapidly. Whether you’ve been recently diagnosed, are in treatment, or looking at what’s next — there may be clinical trials worth exploring.

Not sure where to start?

Walking into an oncology appointment with the right questions changes everything. We put together a quick guide.

This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.

Sources: American Cancer Society, National Cancer Institute, USPSTF, NCCN, Mayo Clinic, NEJM, CA Cancer Journal, peer-reviewed literature (2020–2025), ClinicalTrials.gov.

WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.